Generic Name and Formulations:
Pimecrolimus 1%; crm.
Bausch Health Companies Inc.
Indications for ELIDEL:
Second-line therapy: for short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients when other topical therapies are inadvisable or ineffective.
Adults and Children:
<2yrs: not recommended. ≥2yrs: apply to affected area(s) twice daily. Do not occlude.
Long term safety of topical calcineurin inhibitors has not been established.
Clear infections at treatment site before starting. Netherton's syndrome, generalized erythroderma, malignant or pre-malignant skin conditions: not recommended. Varicella zoster. Eczema herpeticum. Herpes simplex. Consider discontinuing if lymphadenopathy of unknown etiology or acute infectious mononucleosis occurs. Consider discontinuing until warts clear if skin papillomas worsen or are unresponsive. Avoid sun, UV light. Reevaluate if no improvement after 6 weeks. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with CYP3A inhibitors in widespread and/or erythrodermic disease.
Local reactions (eg, burning), nasopharyngitis, pyrexia, cough, headache, others; rare: malignancy (eg, skin, lymphoma).
Crm—30g, 60g, 100g
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL